A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted
therapy in patients with ASS-negative malignant pleural mesothelioma.
Phase:
Phase 2
Details
Lead Sponsor:
Barts & The London NHS Trust
Collaborators:
Cancer Research UK UK: Barts Center for Experimental Cancer Medicine (CECM) for Trial Coordination